Table 1 Clinicopathological correlation of EHD2 overexpression in human HCC.

From: Hypoxia-induced macropinocytosis represents a metabolic route for liver cancer

Clinicopathological phenotype

Number of cases (%)

Mean

P-value

Tumor size

 • ≤5 cm

29

0.2283

0.017*

 • >5 cm

44

1.1430

Direct liver invasion

 • Absent

39

1.0936

0.052

 • Present

29

0.2941

Sex

 • Male

50

1.1520

0.099

 • Female

16

0.0469

Chronic liver disease

 • Normal

11

0.1827

0.202

 • Chronic liver disease and cirrhosis

63

0.8594

Cellular differentiation by Edmondson grading

 • I–III

37

0.5505

0.253

 • IV–VI

36

0.9875

Tumor microsatellite formation

 • Absent

33

0.6415

0.482

 • Present

41

0.9117

Venous invasion

 • Absent

26

1.095

0.493

 • Present

40

0.7905

Cirrhotic liver

 • Normal and chronic hepatitis

31

0.8974

0.534

 • Cirrhosis

43

0.6588

pTNM stage

 • I–II

26

0.6450

0.632

 • I–IV

48

0.8360

Hepatitis C surface antigen by IHC

 • Absent

22

0.6800

0.676

 • Present

12

0.9100

Hepatitis B surface antigen by IHC

 • Absent

18

0.6756

0.858

 • Present

52

0.7762

Plasma hepatitis B surface antigen

 • Absent

14

0.8950

0.983

 • Present

53

0.8808

Tumor encapsulation

 • Absent

44

0.8225

0.94

 • Present

25

0.8552

  1. Mean: average values of EHD2 expression in human HCC samples relative to their adjacent non-tumorous (NT) tissues determined using the formula: ΔCtHCC(EHD2-18S) - ΔCtNT(EHD2-18S).
  2. pTNM: pathological tumor-node-metastasis. Two tailed t-test: *P < 0.05.
Back to article page